Vasogen to List On the American Stock Exchange
TORONTO, Ontario, Nov 22, 1999 (BW HealthWire) -- Vasogen Inc.
(TSE:VAS) (OTCBB: VSOGF) is pleased to announce that the Company's
common shares have been approved for listing on The American Stock
Exchange. Vasogen has chosen Spear Leeds & Kellogg, of New York, New
York, to serve as specialist or "market-maker" on the floor of the
Exchange. The Registrar and Transfer Company of Cranford, New Jersey,
has been retained to act as co-transfer agent in the United States.
Trading on the AMEX under the symbol "MEW" will commence on November
23, 1999. Upon commencement of AMEX trading, the OTC BB listing will be
discontinued.
Vasogen is focused on developing immune modulation therapies to advance
the treatment of cardiovascular, autoimmune and related inflammatory
diseases. These therapies are designed to target fundamental
disease-causing events, providing safe, effective treatment.
Statements contained in this press release, including those pertaining
to scientific and clinical research, commercialization plans, strategic
alliances, and intellectual property protection, other than statements
of historical fact, are forward-looking statements subject to a number
of uncertainties that could cause actual results to differ materially
from statements made. |
